IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene KLK6 Ensembl ENSG00000167755 Chromosome 19 Start 56153700 End 56164741
Description Kallikrein-6 Precursor (EC 3.4.21.-)(Protease M)(Neurosin)(Zyme)(SP59)(Serine protease 9)(Serine protease 18) [Source:UniProtKB/Swiss-Prot;Acc:Q92876]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 6367
     Entrez Gene : 5653
     UCSC : uc002pui.2
     GeneCards : 6367
     RefSeq : NM_001012964
     CCDS : CCDS12811.1
     Uniprot : Q92876
     Interpro : Q92876
     OMIM : 602652
     GeneTests : KLK6
     CGAP : KLK6
     PMID : 9003450

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  37554_at  0.95  2.46e-9  2.83e-8  1.05  1.92e-5  9.07e-5
 HG_U133A  204733_at  0.28  2.44e-2  3.58e-2  2.40  2.61e-68  8.20e-68
 HG_U133_Plus2  204733_at  1.56  1.49e-13  1.70e-12  1.94  1.24e-16  1.18e-15
 Stanford  6066  0.54  2.86e-1  4.88e-1  0.71  1.28e-1  3.21e-1
 Agilent_HS_21.6K  13658  0.35  5.04e-2  1.46e-1  0.56  1.57e-3  7.89e-3

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  204733_at  0.03  9.42e-1  9.97e-1  -0.08  8.27e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 37554_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 204733_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 204733_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 6066    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 13658    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
klk6 ovarian cancer We conclude that KLK6 is transcriptionally upregulated in ovarian cancer, but probably not through alternative mRNA transcript expression, genomic mutation, or steroid hormone induction. 17242704 Human
klk6 ovarian cancer In this study, we measured KLK6 expression in a large series of ovarian tissue cytosols and examined possible mechanisms of KLK6 up-regulation in ovarian cancer. 17242704 Human
klk6 ovarian cancer Using a newly developed enzyme-linked immunosorbent assay (ELISA) with two monoclonal antibodies, we quantified KLK6 expression in ovarian tissue cytosols, and confirmed the upregulation of KLK6 in ovarian cancer and its unfavourable prognostic value. 17242704 Human
klk6 pancreatic cancer At least two kallikreins, KLK6 and KLK10, are significantly up-regulated in pancreatic cancer. 15015574 Human
klk6 cancer KLK6 was found to be expressed in 5/6 cancer libraries and showed the most marked (5-fold) increase in average expression levels in cancer vs. normal. 15015574 Human
klk6 pancreatic cancer X-profiler comparison of two pools of normal and cancerous pancreatic libraries further verified the significant increase of KLK6 expression levels in pancreatic cancer. 15015574 Human
klk6 colon cancer Three kallikrein genes, KLK6, 8 and 10 are overexpressed in colon cancer compared to normal colon, while one kallikrein, KLK1, is down-regulated. 15015574 Human
klk6 cancer While no expression of KLK6 was detected in normal colon, KLK6-specific tags were detectable in 2 cancer libraries. 15015574 Human
klk6 colon adenocarcinoma Similar results were obtained by EST screening; no KLK6 clones were detected in any of the 28 normal libraries examined, while 10 KLK6 EST clones were found in colon adenocarcinoma. 15015574 Human
protease m metastasis Among these genes, we found down-regulation of 11 genes (MMP-9, protease M, uPAR, VEGF, neuropilin, TSP, BPGF, LPA, TGF-beta2, TSP-1, PAR-2) and up-regulation of two genes (connective tissue growth factor, connective tissue activation peptide), which are 12213285 Human
protease m tumor Among these genes, we found down-regulation of 11 genes (MMP-9, protease M, uPAR, VEGF, neuropilin, TSP, BPGF, LPA, TGF-beta2, TSP-1, PAR-2) and up-regulation of two genes (connective tissue growth factor, connective tissue activation peptide), which are 12213285 Human
protease m ovarian tumors Increased expression of protease M in ovarian tumors. 11054022 Human
protease m low malignant potential tumors We also identified the protease M transcript in a differential PCR screen of ovarian tumors and have investigated its expression in 44 ovarian tumors (12 low malignant potential tumors, 32 carcinomas) and 10 normal ovaries using quantitative PCR. 11054022 Human
protease m ovarian tumors We also identified the protease M transcript in a differential PCR screen of ovarian tumors and have investigated its expression in 44 ovarian tumors (12 low malignant potential tumors, 32 carcinomas) and 10 normal ovaries using quantitative PCR. 11054022 Human
protease m carcinomas We also identified the protease M transcript in a differential PCR screen of ovarian tumors and have investigated its expression in 44 ovarian tumors (12 low malignant potential tumors, 32 carcinomas) and 10 normal ovaries using quantitative PCR. 11054022 Human
bssp tumors By monitoring BSSP expression throughout experimental skin carcinogenesis we found strong constitutive expression in hyperplastic epidermis as well as in proliferatively active keratinocytes of benign and malignant skin tumors. 11564170 Mouse
zyme ovarian carcinoma Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. 11124344 Human
protease m other cancers Many of the newly identified kallikrein-like genes are regulated by steroid hormones, and a few kallikreins (NES1, protease M, PSA) are known to be downregulated in breast and possibly other cancers. 10675891 Human
zyme breast cancer Zyme appears to play a role in Alzheimer disease as well as in breast cancer. 10610719 Human
zyme breast carcinoma Zyme is regulated by steroid hormones in the breast carcinoma cell line BT-474. 10610719 Human
neurosin human colon adenocarcinoma A cDNA encoding a precursor for a novel serine protease (neurosin) was cloned from a cDNA library prepared from a human colon adenocarcinoma cell line, COLO 201. 9003450 Human
klk6 ovarian cancer We found that seven KLK genes (KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, and KLK14) are up-regulated in ovarian cancer. 12727843 Human
bssp malignant skin tumors By monitoring BSSP expression throughout experimental skin carcinogenesis we found strong constitutive expression in hyperplastic epidermis as well as in proliferatively active keratinocytes of benign and malignant skin tumors. 11564170 Mouse
bssp hyperplastic By monitoring BSSP expression throughout experimental skin carcinogenesis we found strong constitutive expression in hyperplastic epidermis as well as in proliferatively active keratinocytes of benign and malignant skin tumors. 11564170 Mouse
hk6 breast cyst Highest concentrations of hK6 were found in milk of lactating women, cerebral spinal fluid, nipple aspirate fluid, and breast cyst fluid. hK6 was also detected in male and female serum, in the majority of seminal plasmas and in a small fraction of amnioti 11018688 Human
hk6 ovarian carcinoma RESULTS: We report for the first time, significant increase of serum hK6 concentration in a large proportion of patients with ovarian carcinoma. 11124344 Human
hk6 ovarian cancer The elevations of hK6 appear to be relatively specific for ovarian cancer because other malignancies did not cause any increase in the concentration of this biomarker in serum. 11124344 Human
hk6 ovarian cancer CONCLUSIONS: This is the first report describing significant elevations of hK6 concentration in serum of ovarian cancer patients. 11124344 Human
hk6 ovarian carcinoma These data suggest that hK6 may represent a potential new biomarker for diagnosis and monitoring of ovarian carcinoma. 11124344 Human
hk6 primary tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
hk6 ovarian tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
hk6 ovarian cancers Recent evidence suggests that hK6 may serve as a circulating tumor marker in ovarian cancers. 12016211 Human
hk6 tumor Recent evidence suggests that hK6 may serve as a circulating tumor marker in ovarian cancers. 12016211 Human
hk6 prostate cancer Three other kallikreins, hK6, hK10, and hK11, are emerging new serum biomarkers for ovarian and prostate cancer diagnosis and prognosis. 12142373 Human
hk6 prostate cancer In addition, preliminary reports indicate that three newly identified kallikreins (hK6, hK10 and hK11) are serum biomarkers for diagnosis and monitoring of ovarian and prostate cancer. 12218299 Human
hk6 ovarian tumours We determined the amount of human kallikrein 6 in extracts of 182 ovarian tumours and correlated specific activity (ng hK6 mg(-1) total protein) with clinicopathological variables documented at the time of surgical excision and with outcome (progression f 12232761 Human
hk6 tumours Thirty per cent of the tumours were positive for human kallikrein 6 (>35 ng hK6 mg(-1) total protein). 12232761 Human
hk6 residual tumour Tumour human kallikrein 6 (ng hK6 mg(-1) total protein) was higher in late stage disease, serous histotype, residual tumour >1 cm and suboptimal debulking (>1 cm) (P<0.05). 12232761 Human
hk6 tumour Tumour human kallikrein 6 (ng hK6 mg(-1) total protein) was higher in late stage disease, serous histotype, residual tumour >1 cm and suboptimal debulking (>1 cm) (P<0.05). 12232761 Human
hk6 cancers This family harbours several genes aberrantly expressed in various cancers as well as established (PSA/hK3, hK2) and potential (hK6, hK10) cancer markers. 12439719 Human
hk6 cancer This family harbours several genes aberrantly expressed in various cancers as well as established (PSA/hK3, hK2) and potential (hK6, hK10) cancer markers. 12439719 Human
hk6 ovarian carcinoma Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. 12637468 Human
hk6 primary ovarian carcinoma PATIENTS AND METHODS: We measured, by immunoassay, human kallikrein 6 (hK6) concentration in serum of 97 apparently healthy women, 141 women with benign abdominal diseases, and 146 women with histologically proven primary ovarian carcinoma. 12637468 Human
hk6 ovarian cancer However, hK6 in presurgical serum of ovarian cancer patients was highly elevated (mean, 6.8 micro g/L; P <.001). 12637468 Human
hk6 ovarian carcinoma CONCLUSIONS: Serum hK6 concentration seems to be a new biomarker for ovarian carcinoma and may have value for disease diagnosis and prognosis. 12637468 Human
hk6 ovarian cancer BACKGROUND: Human kallikrein 6 (hK6) is significantly increased in serum in many patients with ovarian cancer and may have a role in amyloid precursor processing and Alzheimer disease. 12709365 Human
hk6 ovarian cancer For example, hK6, 10 and 11 are promising serological markers for ovarian cancer diagnosis. 12876620 Human
hk6 ovarian cancer The serum levels of hK6 might be used as a biomarker for ovarian cancer. 12878203 Human
hk6 tumor The efficient degradation of fibrinogen and collagen types I and IV by hK6 indicated that this kallikrein might play a role in tissue remodeling and/or tumor invasion and metastasis. 12878203 Human
hk6 metastasis The efficient degradation of fibrinogen and collagen types I and IV by hK6 indicated that this kallikrein might play a role in tissue remodeling and/or tumor invasion and metastasis. 12878203 Human
hk6 ovarian cancer To thoroughly characterise the expression of this kallikrein in ovarian cancer, we have developed a novel monoclonal antibody specific to hK6 and employed it in immunohistochemistry with a wide range of ovarian tumour samples. 15305183 Human
hk6 ovarian tumour To thoroughly characterise the expression of this kallikrein in ovarian cancer, we have developed a novel monoclonal antibody specific to hK6 and employed it in immunohistochemistry with a wide range of ovarian tumour samples. 15305183 Human
hk6 ovarian cancer More significantly, high level of kallikrein 6 expression was found in many early-stage and low-grade tumours, and elevated hK6 proteins were found in benign epithelia coexisting with borderline and invasive tissues, suggesting that overexpression of hK6 15305183 Human
hk6 low-grade tumours More significantly, high level of kallikrein 6 expression was found in many early-stage and low-grade tumours, and elevated hK6 proteins were found in benign epithelia coexisting with borderline and invasive tissues, suggesting that overexpression of hK6 15305183 Human
hk6 ovarian cancer Genomic Southern analysis of 19 ovarian tumour samples suggested that gene amplification is one mechanism for the overexpression of hK6 in ovarian cancer. 15305183 Human
hk6 ovarian tumour Genomic Southern analysis of 19 ovarian tumour samples suggested that gene amplification is one mechanism for the overexpression of hK6 in ovarian cancer. 15305183 Human
hk6 tumour We have identified many tumour cell lines that secrete hK6, but its physiological role is unknown. 15557757 Human
hk6 tumour We conclude that hK6 might play a role in the invasion and metastasis of tumour cells and may be a candidate therapeutic target. 15557757 Human
hk6 metastasis We conclude that hK6 might play a role in the invasion and metastasis of tumour cells and may be a candidate therapeutic target. 15557757 Human
hk6 uterine serous papillary carcinoma (uspc) PURPOSE: The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer.EXPERIMENTAL DESIGN: Human kallikrein 6 (hK6) g 15867230 Human
hk6 endometrioid carcinomas EXPERIMENTAL DESIGN: Human kallikrein 6 (hK6) gene expression levels were evaluated in 29 snap-frozen endometrial biopsies, including 13 USPC, 13 endometrioid carcinomas, and 3 normal endometrial cells by real-time PCR. 15867230 Human
hk6 endometrioid carcinoma Finally, hK6 concentration in 79 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 20 women with endometrioid carcinoma, and 17 USPC patients was studied. 15867230 Human
hk6 papillary carcinoma In vitro hK6 secretion was detected in all primary USPC cell lines tested (mean, 11.5 microg/L) and the secretion levels were similar to those found in primary ovarian serous papillary carcinoma cultures (mean, 9.6 microg/L). 15867230 Human
hk6 endometrioid carcinoma In contrast, no hK6 secretion was detectable in primary endometrioid carcinoma and cervical cancer cultures. hK6 serum and plasma concentrations (mean +/- SE) among normal healthy females (2.7 +/- 0.2 microg/L), patients with benign diseases (2.4 +/- 0.2 15867230 Human
hk6 endometrial cancer PURPOSE: The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer.EXPERIMENTAL DESIGN: Human kallikrein 6 (hK6) g 15867230 Human
hk6 endometrioid carcinomas Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA. 15867230 Human
hk6 papillary carcinoma Finally, hK6 concentration in 79 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 20 women with endometrioid carcinoma, and 17 USPC patients was studied.RESULTS: hK6 gene expression levels were significantly higher in USPC wh 15867230 Human
hk6 cervical cancers Finally, hK6 concentration in 79 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 20 women with endometrioid carcinoma, and 17 USPC patients was studied.RESULTS: hK6 gene expression levels were significantly higher in USPC wh 15867230 Human
hk6 endometrioid carcinoma CONCLUSIONS: hK6 is highly expressed in USPC and is released in the plasma and serum of USPC patients. hK6 may represent a novel biomarker for USPC for monitoring early disease recurrence and response to therapy. 15867230 Human
hk6 endometrioid carcinoma In contrast, serum and plasma hK6 values in USPC patients (6.1 +/- 1.1) were significantly higher than those in the noncancer group (P = 0.006), benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005). 15867230 Human
kallikrein 6 ovarian carcinoma Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. 11124344 Human
kallikrein 6 breast cancer Both human kallikrein 6 and human kallikrein 10 are found to be down-regulated in breast cancer cell lines, suggesting that they may be involved in breast cancer pathogenesis and progression. 12087468 Human
kallikrein 6 breast cancer In this study, we investigated the potential value of human kallikrein 6 and human kallikrein 10 as prognostic and predictive factors in breast cancer. 12087468 Human
kallikrein 6 breast tumour We quantified human kallikrein 6 and human kallikrein 10 protein levels in 749 breast tumour cytosolic extracts and correlated this data with various clinicopathological variables and patient outcomes. 12087468 Human
kallikrein 6 tumours Higher human kallikrein 6 and human kallikrein 10 protein levels are associated with younger age, pre-menopausal, status and tumours which are negative for oestrogen and progesterone receptors. 12087468 Human
kallikrein 6 tumour No correlation was found between human kallikrein 6 and human kallikrein 10 levels and tumour size, grade, and nodal status. 12087468 Human
kallikrein 6 breast cancer Taken together, our results suggest that although human kallikrein 6 and human kallikrein 10 are not prognostic markers for breast cancer, human kallikrein 10 is an independent predictive marker for response of tamoxifen therapy. 12087468 Human
kallikrein 6 primary tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
kallikrein 6 ovarian tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
kallikrein 6 ovarian cancer Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. 12232761 Human
kallikrein 6 ovarian tumours We determined the amount of human kallikrein 6 in extracts of 182 ovarian tumours and correlated specific activity (ng hK6 mg(-1) total protein) with clinicopathological variables documented at the time of surgical excision and with outcome (progression f 12232761 Human
kallikrein 6 tumours Thirty per cent of the tumours were positive for human kallikrein 6 (>35 ng hK6 mg(-1) total protein). 12232761 Human
kallikrein 6 tumour Human kallikrein 6-specific immunohistochemical staining of four ovarian tissues that included benign, borderline and malignant lesions indicated a cytoplasmic location of human kallikrein 6 in tumour cells of epithelial origin, although the intensity of 12232761 Human
kallikrein 6 residual tumour Tumour human kallikrein 6 (ng hK6 mg(-1) total protein) was higher in late stage disease, serous histotype, residual tumour >1 cm and suboptimal debulking (>1 cm) (P<0.05). 12232761 Human
kallikrein 6 tumour Tumour human kallikrein 6 (ng hK6 mg(-1) total protein) was higher in late stage disease, serous histotype, residual tumour >1 cm and suboptimal debulking (>1 cm) (P<0.05). 12232761 Human
kallikrein 6 tumour Univariate analysis revealed that patients with tumour human kallikrein 6 positive specific activity were more likely to suffer progressive disease and to die (hazard ratio 1.71 (P=0.015) and 1.88 (P=0.022), respectively). 12232761 Human
kallikrein 6 tumours Multivariate analysis revealed that human kallikrein 6 positivity was retained as an independent prognostic variable in several subgroups of patients, namely those with (low) grade I and II tumours (hazard ratio progression free survival 4.3 (P=0.027) and 12232761 Human
kallikrein 6 ovarian cancer We conclude that tumour kallikrein 6 protein levels have utility as an independent adverse prognostic marker in a subgroup of ovarian cancer patients with otherwise apparently good prognosis. 12232761 Human
kallikrein 6 tumour We conclude that tumour kallikrein 6 protein levels have utility as an independent adverse prognostic marker in a subgroup of ovarian cancer patients with otherwise apparently good prognosis. 12232761 Human
kallikrein 6 ovarian carcinoma Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. 12637468 Human
kallikrein 6 primary ovarian carcinoma PATIENTS AND METHODS: We measured, by immunoassay, human kallikrein 6 (hK6) concentration in serum of 97 apparently healthy women, 141 women with benign abdominal diseases, and 146 women with histologically proven primary ovarian carcinoma. 12637468 Human
kallikrein 6 ovarian cancer BACKGROUND: Human kallikrein 6 (hK6) is significantly increased in serum in many patients with ovarian cancer and may have a role in amyloid precursor processing and Alzheimer disease. 12709365 Human
kallikrein 6 tumor Human kallikrein 6 (protease M/zyme/neurosin) was originally identified based on its aberrant expression in tumor cells and is considered a biomarker for ovarian cancer. 15207701 Human
kallikrein 6 ovarian cancer Human kallikrein 6 (protease M/zyme/neurosin) was originally identified based on its aberrant expression in tumor cells and is considered a biomarker for ovarian cancer. 15207701 Human
kallikrein 6 ovarian cancer Characterisation of human kallikrein 6/protease M expression in ovarian cancer. 15305183 Human
kallikrein 6 ovarian cancer More significantly, high level of kallikrein 6 expression was found in many early-stage and low-grade tumours, and elevated hK6 proteins were found in benign epithelia coexisting with borderline and invasive tissues, suggesting that overexpression of hK6 15305183 Human
kallikrein 6 low-grade tumours More significantly, high level of kallikrein 6 expression was found in many early-stage and low-grade tumours, and elevated hK6 proteins were found in benign epithelia coexisting with borderline and invasive tissues, suggesting that overexpression of hK6 15305183 Human
kallikrein 6 ovarian tumours Quantitative real-time reverse transcription-polymerase chain reactions also showed elevated kallikrein 6 mRNA expression in ovarian tumours. 15305183 Human
kallikrein 6 tumor In addition, a panel of 11 genes known to encode potential tumor markers [mucin 1, transmembrane (MUC1), mucin 16 (CA125), mesothelin, WAP four-disulfide core domain 2 (HE4), kallikrein 6, kallikrein 10, matrix metalloproteinase 2, prostasin, osteopontin, 15161682 Human
kallikrein 6 ovarian cancer Human kallikrein 6 (protease M/zyme/neurosin) is a serine protease that has been suggested to be a serum biomarker for ovarian cancer and may also be involved in pathologies of the CNS. 15255184 Human
kallikrein 6 tumour Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. 15557757 Human
kallikrein 6 ovarian cancer Characterization of human kallikrein 6/prostease M expression in ovarian cancer. 15756267 Human
kallikrein 6 papillary cancer Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. 15867230 Human
kallikrein 6 uterine serous papillary carcinoma (uspc) PURPOSE: The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer.EXPERIMENTAL DESIGN: Human kallikrein 6 (hK6) g 15867230 Human
kallikrein 6 endometrioid carcinomas EXPERIMENTAL DESIGN: Human kallikrein 6 (hK6) gene expression levels were evaluated in 29 snap-frozen endometrial biopsies, including 13 USPC, 13 endometrioid carcinomas, and 3 normal endometrial cells by real-time PCR. 15867230 Human
kallikrein 6 endometrioid carcinoma Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA. 15867230 Human
kallikrein 6 tumor Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA. 15867230 Human
kallikrein 6 papillary carcinoma Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA. 15867230 Human
kallikrein 6 cervical cancers Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA. 15867230 Human
kallikrein 6 endometrial cancer PURPOSE: The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer.EXPERIMENTAL DESIGN: Human kallikrein 6 (hK6) g 15867230 Human
kallikrein 6 endometrioid carcinomas Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA. 15867230 Human
klk6 mammary tumor We show that in normal mammary epithelial cells and mammary tumor cell lines that overexpress the KLK6 gene, splice variants account for approximately 10-20% of all mRNA species. 15207701 Human
klk6 colorectal cancer The purpose of the current study was to quantify the expression of KLK6 in malignant and benign colorectal tissues and to statistically analyze whether KLK6 expression levels correlate with clinicopathologic variables and prognosis in patients with colore 15837738 Human
klk6 liver metastasis Elevated KLK6 expression was significantly correlated with serosal invasion (P < 0.05), liver metastasis (P < 0.05), and advanced Duke's stage (P < 0.01). 15837738 Human
protease m ovarian tumor Immunohistochemical staining of normal ovary and ovarian tumor tissue sections with antibodies generated to protease M derived peptides corroborated the semi-quantitative PCR and Northern analysis data. 11054022 Human
neurosin ovarian carcinoma Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. 11124344 Human
zyme ovarian tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
klk6 colorectal cancer CONCLUSIONS: The results of this study indicated that KLK6 mRNA expression was significantly higher in cancerous than in noncancerous colorectal tissues, and high expression of KLK6 mRNA correlated with serosal invasion, liver metastasis, advanced Duke&ap 15837738 Human
klk6 liver metastasis CONCLUSIONS: The results of this study indicated that KLK6 mRNA expression was significantly higher in cancerous than in noncancerous colorectal tissues, and high expression of KLK6 mRNA correlated with serosal invasion, liver metastasis, advanced Duke&ap 15837738 Human
hk6 breast tumor Highest concentrations of hK6 were found in milk of lactating women, cerebral spinal fluid, nipple aspirate fluid, and breast cyst fluid. hK6 was also detected in male and female serum, in the majority of seminal plasmas and in a small fraction of amnioti 11018688 Human
hk6 cancer This assay will facilitate further studies to examine the possible application of hK6 in diagnostics, including cancer and neurodegenerative disorders. 11018688 Human
hk6 tumours Foci of nesidioblastosis and endocrine dysplasia expressed both kallikreins. hK6 and hK10 were also strongly and diffusely expressed throughout all insulin-, glucagon- and somatostatin-producing tumours. 12769263 Human
hk6 breast cancer Human kallikreins (hK) 2, 3, 6 and 10 are expressed in breast and prostate tissue. hK2 and hK3 (prostate-specific antigen, PSA) are used to screen for prostate cancer. hK6 and hK10 are downregulated in breast cancer compared to normal breast tissue. 14696124 Human
hk6 prostate cancer Human kallikreins (hK) 2, 3, 6 and 10 are expressed in breast and prostate tissue. hK2 and hK3 (prostate-specific antigen, PSA) are used to screen for prostate cancer. hK6 and hK10 are downregulated in breast cancer compared to normal breast tissue. 14696124 Human
hk6 cancer NAF levels were highest for hK6 and lowest for hK2, regardless of cancer and menopausal status. hK3 was detectable in 15/29 (52%) and hK2 in 0/29 serum samples collected from 6 women. hK2 and hK3 were concentrated in NAF vs. matched serum. 14696124 Human
hk6 breast cancer PSA levels were higher in normal pre- than postmenopausal subjects (but not women with breast cancer), whereas levels of hK2, 6 and 10 did not differ by menopausal status. hK2 and PSA were associated with both pre- and postmenopausal breast cancer; hK6 an 14696124 Human
hk6 postmenopausal breast cancer PSA levels were higher in normal pre- than postmenopausal subjects (but not women with breast cancer), whereas levels of hK2, 6 and 10 did not differ by menopausal status. hK2 and PSA were associated with both pre- and postmenopausal breast cancer; hK6 an 14696124 Human
hk6 testicular cancer For example, hK4, hK5, hK6, hK7, hK8, hK10, hK11, hK13 and hK14 are emerging biomarkers for ovarian, breast, prostate and testicular cancer. 15911097 Human
protease m carcinomas The PCR product was labeled with (32)P and a phosphoimager was used to determine the relative expression of the protease M gene compared to internal control beta-tubulin. mRNA expression levels of protease M were significantly elevated in 9 of 12 low mali 11054022 Human
protease m carcinoma Northern blot hybridization showed that the 1.7-kb protease M transcript was abundant in carcinoma but not detected in normal ovary. 11054022 Human
protease m ovarian carcinomas Our results suggest that protease M is frequently overexpressed in ovarian tumors and may therefore contribute to the invasive nature or growth capacity of ovarian carcinomas. 11054022 Human
protease m ovarian tumors Our results suggest that protease M is frequently overexpressed in ovarian tumors and may therefore contribute to the invasive nature or growth capacity of ovarian carcinomas. 11054022 Human
protease m ovarian carcinoma Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. 11124344 Human
protease m ovarian tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
protease m ovarian cancer Human kallikrein 6 (protease M/zyme/neurosin) was originally identified based on its aberrant expression in tumor cells and is considered a biomarker for ovarian cancer. 15207701 Human
protease m tumor Human kallikrein 6 (protease M/zyme/neurosin) was originally identified based on its aberrant expression in tumor cells and is considered a biomarker for ovarian cancer. 15207701 Human
protease m ovarian cancer Human kallikrein 6 (protease M/zyme/neurosin) is a serine protease that has been suggested to be a serum biomarker for ovarian cancer and may also be involved in pathologies of the CNS. 15255184 Human
protease m ovarian cancer Characterisation of human kallikrein 6/protease M expression in ovarian cancer. 15305183 Human
klk6 ovarian cancer Twelve kallikreins, including KLK6, are concurrently upregulated in ovarian cancer. 17242704 Human
protease m low malignant potential tumors The PCR product was labeled with (32)P and a phosphoimager was used to determine the relative expression of the protease M gene compared to internal control beta-tubulin. mRNA expression levels of protease M were significantly elevated in 9 of 12 low mali 11054022 Human
klk6 human gastric cancer Herein, we investigated the clinicopathologic and biological significance of KLK6 gene expression in human gastric cancer. 16203767 Human
klk6 gastric cancer PATIENTS AND METHODS: Using real-time reverse transcription-PCR, we analyzed the KLK6 expression status with respect to various clinicopathologic variables in 66 patients with gastric cancer. 16203767 Human
klk6 gastric cancer In addition, we established a KLK6 stably suppressed gastric cancer cell line (MKN28) using small interfering RNA-mediated gene silencing, and investigated its effects on the cell proliferation rate, cell cycle, and invasiveness. 16203767 Human
klk6 gastric cancer CONCLUSIONS: The KLK6 gene is markedly overexpressed in gastric cancer tissue and its expression status may be a powerful prognostic indicator for patients with gastric cancer. 16203767 Human
klk6 gastric cancer Our findings also suggest that KLK6 may possibly be a novel target for gastric cancer therapy by gene-silencing procedures. 16203767 Human
klk6 ovarian cancer Kallikreins 6 (KLK6) and 10 (KLK10) are elevated in tumour cells, serum and ascites fluid of ovarian cancer patients and correlate with disease prognosis. 16557045 Human
klk6 tumour Kallikreins 6 (KLK6) and 10 (KLK10) are elevated in tumour cells, serum and ascites fluid of ovarian cancer patients and correlate with disease prognosis. 16557045 Human
klk6 ovarian cancer We hypothesized that KLK6 and KLK10 can be utilized to monitor dissemination of ovarian cancer cells in blood and ascites fluid of ovarian cancer patients. 16557045 Human
klk6 cancer RESULTS: Screening for disseminated cancer cells in blood from 24 ovarian cancer patients, with RT-PCR for KLK6 mRNA, resulted in 75% positivity; however, this was not different from the positivity of normal controls. 16557045 Human
klk6 ovarian cancer RESULTS: Screening for disseminated cancer cells in blood from 24 ovarian cancer patients, with RT-PCR for KLK6 mRNA, resulted in 75% positivity; however, this was not different from the positivity of normal controls. 16557045 Human
klk6 other cancer Screening of ascites fluid of ovarian cancer patients revealed 90% positivity for KLK6 and KLK10 mRNA compared with 33% for other cancer types. 16557045 Human
klk6 ovarian cancer Screening of ascites fluid of ovarian cancer patients revealed 90% positivity for KLK6 and KLK10 mRNA compared with 33% for other cancer types. 16557045 Human
klk6 breast tumor Human kallikrein 6 (KLK6) was identified based on its transient upregulation in a primary breast tumor and its subsequent silencing in a metastatic tumor from the same patient. 16800739 Human
klk6 metastatic tumor Human kallikrein 6 (KLK6) was identified based on its transient upregulation in a primary breast tumor and its subsequent silencing in a metastatic tumor from the same patient. 16800739 Human
klk6 cancer The molecular mechanism(s) underlying the deregulated expression of KLK6 during cancer progression are currently unknown. 16800739 Human
klk6 breast cancer KLK6 can be reactivated in non-expressing breast cancer cells by treatment with 5-aza-2'-deoxycytidine (5-aza-dC), a compound causing DNA demethylation. 16800739 Human
klk6 breast cancer In some breast cancer cell lines, KLK6 expression could be restored by the vitamin D3 analog EB1089. 16800739 Human
klk6 breast cancer Our data indicate that transcriptional deregulation of KLK6 in cancer cells during breast cancer progression is complex and certainly not uniform in different tumors, involving epigenetic mechanisms as well as pathways regulated by nuclear receptors. 16800739 Human
klk6 cancer Our data indicate that transcriptional deregulation of KLK6 in cancer cells during breast cancer progression is complex and certainly not uniform in different tumors, involving epigenetic mechanisms as well as pathways regulated by nuclear receptors. 16800739 Human
klk6 tumors Our data indicate that transcriptional deregulation of KLK6 in cancer cells during breast cancer progression is complex and certainly not uniform in different tumors, involving epigenetic mechanisms as well as pathways regulated by nuclear receptors. 16800739 Human
hk6 ovarian cancers In ovarian cancers that lacked CA125, all specimens (100%) expressed human kallikrein 10 (HK10), human kallikrein 6 (HK6), osteopontin (OPN), and claudin 3. 16061277 Human
hk6 salivary gland tumors The aim of this study was to determine whether hK6 is expressed in salivary gland tissues and salivary gland tumors (both benign and malignant), using an immunohistochemical method. 16286664 Human
hk6 other tumors In all other tumors exhibiting both types of cells, hK6 staining was similar in both duct-like and non-duct-like cells. 16286664 Human
hk6 salivary gland tumors Results of this study show that salivary gland tumors express hK6, apparently downregulated in comparison with normal salivary gland tissue, and that this expression is not specific for any of the tumors studied. 16286664 Human
hk6 tumors Results of this study show that salivary gland tumors express hK6, apparently downregulated in comparison with normal salivary gland tissue, and that this expression is not specific for any of the tumors studied. 16286664 Human
hk6 tumors In conclusion, although the immunohistochemical expression of hK5, hK6, hK10 and hK11 was downregulated in RCC, tumors of high grade and late stage expressed one or more of the above kallikreins in a higher percentage of cases, and hK6 may predict a poor 16340244 Human
hk6 ovarian cancer In the present study, OV-MZ-6 ovarian cancer cells were stably co-transfected with plasmids expressing hK4, hK5, hK6, and hK7. 16800744 Human
hk6 tumor Simultaneous expression of hK4, hK5, hK6, and hK7 resulted in a remarkable 92% mean increase in tumor burden compared to the vector-control cell line. 16800744 Human
hk6 epithelial ovarian tumors We previously found that hK6 and hK10 are highly overexpressed in epithelial ovarian tumors and demonstrated that serum levels of hK6 and hK10 are valuable biomarkers for ovarian cancer diagnosis and prognosis. 16864975 Human
hk6 ovarian cancer We previously found that hK6 and hK10 are highly overexpressed in epithelial ovarian tumors and demonstrated that serum levels of hK6 and hK10 are valuable biomarkers for ovarian cancer diagnosis and prognosis. 16864975 Human
hk6 ovarian cancer Methods: Protein concentrations of hK6 and hK10 in ovarian cancer ascites fluids were measured with ELISA-type immunoassays. hK6 and hK10 were purified from the ascites fluids with immunoaffinity columns, followed by reverse-phase high performance liquid 16864975 Human
hk6 ovarian cancer RESULTS: hK6 and hK10 were present in ovarian cancer ascites fluid at concentrations ranging from 0.2-571 and 0.7-220 microg/l, respectively. 16864975 Human
hk6 ovarian tumor Conclusions: The majority of hK6 secreted by the ovarian tumor cells into the ascites fluid are present in the uncomplexed, zymogen form, possessing weak trypsin-like enzymatic activity. 16864975 Human
protease m ovarian cancer Protease M expression was examined in mammary, prostate, and ovarian cancer, as well as normal, cells and tissues. 8898378 Human
protease m mammary carcinoma Stable transfectants expressing the protease M gene were produced in mammary carcinoma cells. 8898378 Human
protease m mammary carcinomas CONCLUSIONS: Protease M expression (mRNA) may be a useful marker in the detection of primary mammary carcinomas, as well as primary ovarian cancers. 8898378 Human
protease m primary ovarian cancers CONCLUSIONS: Protease M expression (mRNA) may be a useful marker in the detection of primary mammary carcinomas, as well as primary ovarian cancers. 8898378 Human
zyme primary tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
hk6 rcc Fifty-seven RCC cases were immunostained for hK5, 70 for hK6, 70 for hK10 and 69 for hK11. 16340244 Human
hk6 rcc In RCC, immunohistochemical expression was decreased: 33 of 57 cases (58%) were positive for hK5, 27 of 70 (39%) for hK6, 46 of 70 (66%) for hK10 and 32 of 69 (46%) for hK11. 16340244 Human
hk6 rcc In conclusion, although the immunohistochemical expression of hK5, hK6, hK10 and hK11 was downregulated in RCC, tumors of high grade and late stage expressed one or more of the above kallikreins in a higher percentage of cases, and hK6 may predict a poor 16340244 Human
bssp carcinogenesis Keratinocyte-specific onset of serine protease BSSP expression in experimental carcinogenesis. 11564170 Mouse
bssp carcinogenesis By monitoring BSSP expression throughout experimental skin carcinogenesis we found strong constitutive expression in hyperplastic epidermis as well as in proliferatively active keratinocytes of benign and malignant skin tumors. 11564170 Mouse
protease m primary tumors Zyme/protease M/neurosin/human kallikrein 6 (hK6) is a member of the human kallikrein family of trypsin-like serine proteinases and was originally identified as being down-regulated in metastatic breast and ovarian tumors when compared with corresponding 12016211 Human
protease m oncogenes Many of the genes upregulated in USPC were found to represent adhesion molecules, secreted proteins and oncogenes, such as L1 cell adhesion molecule, claudin-3 and claudin-4, kallikrein 6 (protease M) and kallikrein 10 (NES1), interleukin-6 and c-erbB2. 15785748 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.